Overview

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.

Eligibility

Inclusion Criteria:

• Female, aged ≥18 and ≤70 years;
• Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);
• Completed neoadjuvant treamtment and surgery (within 4 years after surgery);
• Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);
• ECOG 0-1

Exclusion Criteria:

• Metastatic disease (Stage IV);
• Female patients who are pregnancy or lactation;
• Uncontrollable puncture site infection or systemic infection;